Activity of carbapenems and tigecycline against ESBL-producing Escherichia coli and Klebsiella spp.

ABSTRACT The indiscriminate use of carbapenems in the fight against multidrug resistant Gram-negative bacteria leads to the emergence of resistance to these antimicrobial agents. We examine the in vitro activity of carbapenems and tigecycline against ESBL-producing E. coli and Klebsiella spp. isolat...

Full description

Saved in:
Bibliographic Details
Main Authors: Caio Fernando de Oliveira (Author), Fernando Ferrugem (Author), Renan V. Schmidt (Author), Daniel Prá (Author), Jorge André Horta (Author)
Format: Book
Published: Sociedade Brasileira de Patologia Clínica, 2018-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT The indiscriminate use of carbapenems in the fight against multidrug resistant Gram-negative bacteria leads to the emergence of resistance to these antimicrobial agents. We examine the in vitro activity of carbapenems and tigecycline against ESBL-producing E. coli and Klebsiella spp. isolated in a single hospital at two different periods eight years apart. Overall resistance to carbapenems ranged from 18.7% in 2007 to 19.1% in 2015/2016. We found no isolates resistant to tigecycline, but two intermediary profiles in the 2015/2016 period. Tigecycline is an important option for treating multidrug resistant Gram-negative infections and helps in the fight against global dissemination of resistance to carbapenems.
Item Description:1678-4774
10.5935/1676-2444.20180007